Katherine Cheng

Katie Cheng is a partner in the Trials, Investigations, and Litigation practice at Goodwin and a member of the firm’s Life Sciences and Technology industry groups and Antitrust and Competition group. An experienced litigator and trial lawyer, Katie represents clients in high-stakes disputes involving competition issues, innovation, and rapidly evolving markets.

Katie’s practice centers on antitrust and other complex competitive disputes, including matters involving unfair competition, false advertising, business torts, contract claims, and intellectual property. Many of her clients operate in industries undergoing technological change, regulatory uncertainty, or other market disruption, and she develops litigation strategies that account for both the immediate dispute and her clients’ broader competitive and business objectives.

Katie represents plaintiffs and defendants at every stage of litigation, from pre-litigation counseling through dispositive motions, complex discovery, expert proceedings, trial, and appeal. She also regularly advises on litigation risk and strategy.

Katie’s experience includes:

• Represented Teva in an antitrust class action alleging that its settlement of patent litigation with Gilead over generic versions of the HIV medications Viread®, Atripla®, and Truvada® included unlawful “reverse payments” that delayed generic entry. Plaintiffs sought $3.8 billion in damages, and the case resulted in a defense verdict after a six-week jury trial in California federal court
• Representing Teva in defense of several class action cases raising antitrust, Lanham Act, RICO, and other claims involving Teva’s branded multiple sclerosis product, Copaxone
• Represented a brand pharmaceutical company in Hatch-Waxman patent litigation concerning competing inhaled pharmaceutical products. Bench trial resulted in a favorable decision finding that asserted patent claims were valid and infringed. Stand-up member of trial team
• Representing certain Chinese respondents in defending unfair competition claims in a Section 337 investigation before the U.S. International Trade Commission concerning disposable vapes and other closed-system electronic nicotine delivery system devices
• Serving as lead counsel for a tech-focused strategic venture capital firm in employment discrimination litigation involving claims under the Family and Medical Leave Act, Title VII, and state law
• Represented national mortgage lender in putative nationwide class action asserting an algorithmic pricing theory 
• Represented established pharmaceutical company in Lanham Act, unfair competition, and other business tort claims arising from allegedly false statements by a competitor
• Represented a Silicon Valley healthcare technology startup in a jury trial and appeal against a pharmacy benefits manager regarding various healthcare, tort, and contract claims. Stand-up member of trial team
• Represented a major healthcare insurer against a private equity-backed provider group regarding antitrust and contract claims, winning the only claims tried before the arbitration panel*
• Represented a major cable provider in a jury trial involving antitrust tying claims, with favorable post-trial decision affirmed on appeal*

*Denotes experience prior to joining Goodwin.

Katie serves on the National Women’s Law Center’s Leadership Advisory Committee and as a co-chair of the Women’s Forum for the Asian Pacific American Bar Association of DC. She also participated in the Leadership Council on Legal Diversity’s 2021 Pathfinder program and 2026 Fellows program. At Goodwin, Katie has served as a co-local council leader of Mosaic for the Washington, DC office for multiple years.

Prior to joining Goodwin, Katie practiced at Boies Schiller Flexner LLP and Latham & Watkins LLP. She also served as a law clerk to the Honorable Alan C. Kay in the United States District Court for the District of Hawaii. During law school, she successfully argued a pro bono appeal before the Ninth Circuit. Prior to law school, she was a paralegal specialist at the U.S. Department of Justice, Federal Programs Branch.

Katie was recognized by The Legal 500 US 2026 as a recommended lawyer in Antitrust: Civil Litigation/Class Action: Defense. Katie has also been recognized by Benchmark Litigation’s 40 and Under List 2026. Earlier in her career, she was also recognized multiple times by Best Lawyers as a One to Watch in Antitrust Law (2021, 2022, 2023). 

• Speaker, “The Future of Life Sciences Antitrust,” Goodwin Webinar, February 12, 2026
• Co-Author, “CMS’s Proposed Rule Improves Prior Authorization Processes,” New York Law Journal, April 12, 2023
• Co-Author, “340B Entities Face Increased Challenges in a Shifting Regulatory and Enforcement Landscape,” MedCity News, August 11, 2022